Hennion & Walsh Asset Management Inc. Invests $1.70 Million in Taysha Gene Therapies, Inc. $TSHA

Hennion & Walsh Asset Management Inc. bought a new position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 308,457 shares of the company’s stock, valued at approximately $1,697,000. Hennion & Walsh Asset Management Inc. owned 0.11% of Taysha Gene Therapies as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of TSHA. Xponance Inc. raised its position in Taysha Gene Therapies by 29.1% during the 3rd quarter. Xponance Inc. now owns 16,575 shares of the company’s stock worth $54,000 after buying an additional 3,738 shares during the last quarter. Principal Financial Group Inc. raised its holdings in shares of Taysha Gene Therapies by 33.6% during the third quarter. Principal Financial Group Inc. now owns 16,251 shares of the company’s stock worth $53,000 after purchasing an additional 4,091 shares during the last quarter. ST Germain D J Co. Inc. lifted its position in Taysha Gene Therapies by 81.8% during the third quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock valued at $32,000 after purchasing an additional 4,333 shares during the period. Legal & General Group Plc boosted its holdings in Taysha Gene Therapies by 25.8% in the third quarter. Legal & General Group Plc now owns 23,149 shares of the company’s stock valued at $76,000 after purchasing an additional 4,754 shares during the last quarter. Finally, Quantum Private Wealth LLC grew its position in Taysha Gene Therapies by 0.7% during the 3rd quarter. Quantum Private Wealth LLC now owns 822,076 shares of the company’s stock worth $2,688,000 after purchasing an additional 6,100 shares during the period. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Down 3.6%

Shares of NASDAQ TSHA opened at $4.31 on Thursday. The stock has a market cap of $1.24 billion, a PE ratio of -12.68 and a beta of 1.02. The company has a current ratio of 12.23, a quick ratio of 12.23 and a debt-to-equity ratio of 0.20. Taysha Gene Therapies, Inc. has a 12-month low of $1.05 and a 12-month high of $6.02. The company has a 50-day moving average of $4.56 and a 200 day moving average of $4.62.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. The business had revenue of $5.49 million during the quarter, compared to analysts’ expectations of $1.89 million. As a group, sell-side analysts predict that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Insider Activity at Taysha Gene Therapies

In other Taysha Gene Therapies news, CEO Sean P. Nolan sold 41,312 shares of the company’s stock in a transaction on Monday, January 26th. The stock was sold at an average price of $4.61, for a total value of $190,448.32. Following the completion of the sale, the chief executive officer directly owned 2,908,257 shares in the company, valued at $13,407,064.77. This represents a 1.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Sukumar Nagendran sold 26,918 shares of the business’s stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $4.61, for a total transaction of $124,091.98. Following the transaction, the insider directly owned 1,317,389 shares in the company, valued at approximately $6,073,163.29. The trade was a 2.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 598,623 shares of company stock valued at $2,822,188. 3.78% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. The Goldman Sachs Group set a $11.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, December 4th. Wall Street Zen raised Taysha Gene Therapies from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Raymond James Financial reissued a “strong-buy” rating and issued a $13.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. UBS Group set a $11.00 target price on Taysha Gene Therapies in a research note on Thursday, December 4th. Finally, Truist Financial raised shares of Taysha Gene Therapies to a “strong-buy” rating in a research note on Wednesday, March 25th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $11.09.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.